Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

Double-blind, Randomized, Parallel Design, Active-controlled Phase 1 Clinical Trial to Evaluate the Efficacy and Safety of DWP712 and Botox® in Adult Patients in Need of Moderate to Severe Glabellar Lines

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06212960

Enrollment

Registered

2024-01-19

Start date

2023-11-28

Completion date

2024-03-21

Last updated

2024-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glabellar Lines

Brief summary

To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.

Interventions

BIOLOGICALDWP712

Clostridium botulinum Toxin

BIOLOGICALBOTOX®

Clostridium botulinum Toxin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

19 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Subjects with facial wrinkle scale (FWS) score of visual appearance of glabellar lines ≥2 (moderate) at maximum frown as assessed by the investigator at screening

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Number of occurrences for grade 3 or higher adverse drug reactions (ADRs) according to CTCAE 5.0	At 4, 8, 12 week after the injection

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026